Genprex closed at $2.14 on Nov 4, down 7.36%, 99.1% below its 52-week closing high. Volume of 251.1K shares was 1.27× its 20-day average (above normal).
Split-adjusted performance: -18.0% over one month, -89.1% over six months, -98.2% over one year.
Short interest was 124.9K shares at the Oct 15 settlement, up 28.7% from the prior report (15.3% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| GNPXGenprex | $2.14 | −7.36% | −89.1% | — | — | — | $1.8M | |
| PPCBPropanc Biopharma | $1.79 | +4.68% | −92.9% | — | — | — | $1.8M | Compare |
| OGENOragenics | $0.3720 | +0.51% | −40.0% | — | — | — | $1.7M | Compare |
| KAPAKairos Pharma | $0.4897 | −3.03% | −87.4% | — | — | — | $1.7M | Compare |
| KPTIKaryopharm Therapeutics | $0.0729 | −17.44% | −99.2% | −11.9% | −200.5% | — | $1.7M | Compare |
| SBFMSunshine Biopharma | $2.65 | −3.28% | −98.8% | −1.6% | −16.9% | — | $2.0M | Compare |
| ELABPMGC Holdings | $1.92 | −1.03% | −91.0% | — | −225.1% | — | $1.6M | Compare |
| GOVXGeoVax Labs, Inc. New | $0.1680 | +2.38% | −89.8% | −100.0% | — | — | $1.5M | Compare |
| ERNAErnexa Therapeutics | $1.99 | −1.49% | −67.1% | — | — | — | $2.3M | Compare |
No recent articles focused on Genprex. 1 articles mention it in passing.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
